論文

2022年4月

Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model

Investigational New Drugs
  • Hideki Kashiwagi
  • Shinji Kawabata
  • Kohei Yoshimura
  • Yusuke Fukuo
  • Takuya Kanemitsu
  • Koji Takeuchi
  • Ryo Hiramatsu
  • Kai Nishimura
  • Kazuki Kawai
  • Takushi Takata
  • Hiroki Tanaka
  • Tsubasa Watanabe
  • Minoru Suzuki
  • Shin Ichi Miyatake
  • Hiroyuki Nakamura
  • Masahiko Wanibuchi
  • 全て表示

40
2
開始ページ
255
終了ページ
264
記述言語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s10637-021-01201-7

Introduction Boron neutron capture therapy (BNCT) is a biologically targeted, cell-selective particle irradiation therapy that utilizes the nuclear capture reaction of boron and neutron. Recently, accelerator neutron generators have been used in clinical settings, and expectations for developing new boron compounds are growing. Methods and Results In this study, we focused on serum albumin, a well-known drug delivery system, and developed maleimide-functionalized closo-dodecaborate albumin conjugate (MID-AC) as a boron carrying system for BNCT. Our biodistribution experiment involved F98 glioma-bearing rat brain tumor models systemically administered with MID-AC and demonstrated accumulation and long retention of boron. Our BNCT study with MID-AC observed statistically significant prolongation of the survival rate compared to the control groups, with results comparable to BNCT study with boronophenylalanine (BPA) which is the standard use of in clinical settings. Each median survival time was as follows: untreated control group; 24.5 days, neutron-irradiated control group; 24.5 days, neutron irradiation following 2.5 h after termination of intravenous administration (i.v.) of BPA; 31.5 days, and neutron irradiation following 2.5 or 24 h after termination of i.v. of MID-AC; 33.5 or 33.0 days, respectively. The biological effectiveness factor of MID-AC for F98 rat glioma was estimated based on these survival times and found to be higher to 12. This tendency was confirmed in BNCT 24 h after MID-AC administration. Conclusion MID-AC induces an efficient boron neutron capture reaction because the albumin contained in MID-AC is retained in the tumor and has a considerable potential to become an effective delivery system for BNCT in treating high-grade gliomas.

リンク情報
DOI
https://doi.org/10.1007/s10637-021-01201-7
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34816337
Scopus
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85119837710&origin=inward
Scopus Citedby
https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85119837710&origin=inward
ID情報
  • DOI : 10.1007/s10637-021-01201-7
  • ISSN : 0167-6997
  • eISSN : 1573-0646
  • PubMed ID : 34816337
  • SCOPUS ID : 85119837710

エクスポート
BibTeX RIS